Loncar Cancer Immunotherapy ETF Forecast

Weaker technical forecast for Loncar Cancer Immunotherapy as ETF downgraded to Hold/Accumulate.
(Updated on Apr 24, 2024)

CNCR Signals & Forecast

A buy signal was issued from a pivot bottom point on Friday, April 19, 2024, and so far it has risen 0.85%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Loncar Cancer Immunotherapy ETF holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $14.38 and $15.81. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day which is technical positive. One should, however, note that this ETF may have low liquidity in periods, which increases the general risk. The very low volume increases the risk and reduces the other technical signals issued. The ETF had a Golden Star Signal on Wednesday, May 31, 2023 in the long-term chart.

Golden Star Signal is when the short-term moving average, the long-term moving average, and price line meet in a special combination. This combination is very rare and often followed by long and strong gains for the ETF in question.

Support, Risk & Stop-loss for Loncar Cancer Immunotherapy ETF

Loncar Cancer Immunotherapy finds support from accumulated volume at $14.21 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This ETF has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the ETF moved $0.295 between high and low, or 2.07%. For the last week the ETF has had daily average volatility of 2.47%.

Our recommended stop-loss: $13.37 (-6.03%) (This ETF has medium daily movements and this gives medium risk. There is a buy signal from a pivot bottom found 3 days ago.)

Trading Expectations (CNCR) For The Upcoming Trading Day Of Thursday 25th

For the upcoming trading day on Thursday, 25th we expect Loncar Cancer Immunotherapy ETF to open at $14.33, and during the day (based on 14 day Average True Range), to move between $13.78 and $14.68, which gives a possible trading interval of +/-$0.452 (+/-3.17%) up or down from last closing price. If Loncar Cancer Immunotherapy ETF takes out the full calculated possible swing range there will be an estimated 6.35% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $14.21 (0.14%) than the resistance at $14.57 (2.39%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Loncar Cancer Immunotherapy ETF ETF A Buy?

Loncar Cancer Immunotherapy holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this ETF since the last evaluation from a Buy to a Hold/Accumulate candidate.

Current score: 0.618 Hold/Accumulate Downgraded

Predicted Opening Price for Loncar Cancer Immunotherapy ETF of Thursday, April 25, 2024

The predicted opening price is based on yesterday's movements between high, low, and closing price.